FDA Puts Breast Milk Nutrient Testers into Official Safety Category
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting the breast milk macronutrients test system into Class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps companies bring these helpful devices to moms and babies faster and safer. The new rules took effect on May 9, 2025, making it easier and quicker to get these tests to market without extra costs.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Breast milk macronutrient tests cleared faster
The FDA officially classified the breast milk macronutrients test system as Class II (special controls) effective May 9, 2025; the classification was applicable on December 21, 2018. The device is defined to measure fat, protein, and total carbohydrate in human breast milk and the FDA says the change will enhance patient access and reduce regulatory burdens so these tests can reach moms and babies more quickly.
Manufacturers must meet specific test and label rules
Companies that market a breast milk macronutrients test system must follow Class II special controls and submit a premarket notification under section 510(k). Required special controls include a traceability plan, precision studies using at least three breast milk specimens at low/medium/high concentrations with measurements from a minimum of three laboratory sites, accuracy data from at least one laboratory site, interference testing (including hemoglobin and medications), and labeling with a statement that results are only an aid in nutritional management.
Enables future devices to use 510(k) pathway
Because FDA classified this device into Class II via the De Novo process, the breast milk macronutrients test system can serve as a predicate for future similar devices, allowing other device sponsors to use the less-burdensome 510(k) process rather than a De Novo request or premarket approval.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08146, Medical Devices; Immunology and Microbiology Devices; Classification of the Cytomegalovirus Nucleic Acid Detection Device for Congenital Cytomegalovirus Infection
The FDA is officially classifying a special test that detects cytomegalovirus (CMV) in newborns as a Class II device, meaning it has special safety rules but is easier to get to patients. This change helps make sure the test is safe and effective while speeding up access to this important tool for babies and families. The new rules took effect on May 9, 2025, and could lower costs and delays for companies making these tests.
Next: 2025-08148, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Voriconazole Test System
The FDA is officially classifying the voriconazole test system as a Class II device with special safety rules, making it safer and easier to get to patients. This change lowers regulatory hurdles, speeding up access to this important medical test without extra costs. The new classification is effective May 9, 2025, benefiting device makers and patients alike.